Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Exp Hematol

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    October 2017
  1. HASSAN C, Afshinnekoo E, Li S, Wu S, et al
    Genetic and epigenetic heterogeneity and the impact on cancer relapse.
    Exp Hematol. 2017;54:26-30.
    PubMed     Text format     Abstract available


    September 2017
  2. GREGORY MA, Nemkov T, Reisz JA, Zaberezhnyy V, et al
    Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Exp Hematol. 2017 Sep 22. pii: S0301-472X(17)30776.
    PubMed     Text format     Abstract available


  3. LAGACE K, Barabe F, Hebert J, Cellot S, et al
    Identification of novel biomarkers for MLL translocated acute myeloid leukemia.
    Exp Hematol. 2017 Sep 11. pii: S0301-472X(17)30758.
    PubMed     Text format     Abstract available


  4. CHAN LN, Muschen M
    B-cell identity as a metabolic barrier against malignant transformation.
    Exp Hematol. 2017;53:1-6.
    PubMed     Text format     Abstract available


    July 2017
  5. ZHANG J, Griffith M, Miller CA, Griffith OL, et al
    Comprehensive discovery of non-coding RNAs in acute myeloid leukemia cell transcriptomes.
    Exp Hematol. 2017 Jul 28. pii: S0301-472X(17)30701.
    PubMed     Text format     Abstract available


  6. YALCIN A, Kovarbasic M, Wehrle J, Claus R, et al
    The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
    Exp Hematol. 2017 Jul 28. pii: S0301-472X(17)30702.
    PubMed     Text format     Abstract available


  7. MARTINO B, Mammi C, Labate C, Rodi S, et al
    Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib.
    Exp Hematol. 2017 Jul 28. pii: S0301-472X(17)30663.
    PubMed     Text format     Abstract available


  8. CARRETTA M, de Boer B, Jaques J, Antonelli A, et al
    Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.
    Exp Hematol. 2017;51:36-46.
    PubMed     Text format     Abstract available


  9. LEPRETRE S, Graux C, Touzart A, Macintyre E, et al
    Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators.
    Exp Hematol. 2017;51:7-16.
    PubMed     Text format     Abstract available


    June 2017
  10. LAING AA, Harrison CJ, Gibson BES, Keeshan K, et al
    Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Exp Hematol. 2017 Jun 28. pii: S0301-472X(17)30237.
    PubMed     Text format     Abstract available


  11. SANDA T, Leong WZ
    TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
    Exp Hematol. 2017 Jun 23. pii: S0301-472X(17)30231.
    PubMed     Text format     Abstract available


  12. SLOMA I, Mitjavila-Garcia M, Feraud O, Griscelli F, et al
    Whole genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.
    Exp Hematol. 2017 Jun 7. pii: S0301-472X(17)30192.
    PubMed     Text format     Abstract available


  13. PORTER SN, Magee JA
    PRKCH regulates hematopoietic stem cell function and predicts poor prognosis in acute myeloid leukemia.
    Exp Hematol. 2017 Jun 5. pii: S0301-472X(17)30190.
    PubMed     Text format     Abstract available


    May 2017
  14. OMORI I, Yamaguchi H, Miyake K, Miyake N, et al
    D816V mutation in the KIT gene activation loop has a greater cell proliferative and anti-apoptotic ability than N822K mutation in core binding factor-acute myeloid leukemia.
    Exp Hematol. 2017 May 12. pii: S0301-472X(17)30146.
    PubMed     Text format     Abstract available


  15. SHEN Y, Chen TJ, Lacorazza HD
    Novel tumor suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
    Exp Hematol. 2017 May 4. pii: S0301-472X(17)30141.
    PubMed     Text format     Abstract available


    April 2017
  16. SADOVNIK I, Herrmann H, Eisenwort G, Blatt K, et al
    Expression of CD25 on Leukemic Stem Cells in BCR-ABL1+ CML: Potential Diagnostic Value and Functional Implications.
    Exp Hematol. 2017 Apr 27. pii: S0301-472X(17)30135.
    PubMed     Text format     Abstract available


  17. VAN GILS N, Verhagen HJMP, Smit L
    Reprogramming acute myeloid leukemia into sensitivity for retinoic acid-driven differentiation.
    Exp Hematol. 2017 Apr 26. pii: S0301-472X(17)30139.
    PubMed     Text format     Abstract available


  18. SASAKI T, Rivera-Mulia JC, Vera D, Zimmerman J, et al
    Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.
    Exp Hematol. 2017 Apr 19. pii: S0301-472X(17)30136.
    PubMed     Text format     Abstract available


    March 2017
  19. GHOSH J, Kapur R
    Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Exp Hematol. 2017 Mar 22. pii: S0301-472X(17)30063.
    PubMed     Text format     Abstract available


  20. CLARKE CJ, Holyoake TL
    Preclinical approaches in chronic myeloid leukemia: from cells to systems.
    Exp Hematol. 2017;47:13-23.
    PubMed     Text format     Abstract available


  21. UTTARKAR S, Frampton J, Klempnauer KH
    Targeting the transcription factor Myb by small-molecule inhibitors.
    Exp Hematol. 2017;47:31-35.
    PubMed     Text format     Abstract available


  22. BOGEN A, Buske C, Hiddemann W, Bohlander SK, et al
    Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.
    Exp Hematol. 2017;47:54-63.
    PubMed     Text format     Abstract available


    February 2017
  23. CAO H, Xu Y, de Necochea-Campion R, Baylink DJ, et al
    Application of vitamin D and vitamin D analogs in acute myelogenous leukemia.
    Exp Hematol. 2017 Feb 4. pii: S0301-472X(17)30050.
    PubMed     Text format     Abstract available


  24. YOKOYAMA A
    Transcriptional activation by MLL fusion proteins in leukemogenesis.
    Exp Hematol. 2017;46:21-30.
    PubMed     Text format     Abstract available


    January 2017
  25. CANDONI A, De Marchi F, Zanini F, Zannier ME, et al
    Predictive value of pre transplant molecular minimal residual disease assessment by wt1 gene expression in flt3 positive acute myeloid leukemia.
    Exp Hematol. 2017 Jan 31. pii: S0301-472X(17)30015.
    PubMed     Text format     Abstract available


  26. AN X, Liu J, Wang N, Wang D, et al
    AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.
    Exp Hematol. 2017;45:36-44.
    PubMed     Text format     Abstract available


    December 2016
  27. ORTI G, Barba P, Fox L, Salamero O, et al
    Donor Lymphocyte Infusions in AML and MDS: enhancing the Graft-versus-Leukemia effect.
    Exp Hematol. 2016 Dec 24. pii: S0301-472X(16)30772.
    PubMed     Text format    


    November 2016
  28. CHURCHMAN ML, Mullighan CG
    Ikaros: exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.
    Exp Hematol. 2016 Nov 16. pii: S0301-472X(16)30703.
    PubMed     Text format     Abstract available


  29. ZHOU X, Li Z, Zhou J
    TNF-alpha in onset and progression of leukemia.
    Exp Hematol. 2016 Nov 7. pii: S0301-472X(16)30660.
    PubMed     Text format     Abstract available


  30. LEMOLI RM, Parisi S, Curti A
    Novel Strategies of Adoptive Immunotherapy: How Natural Killer Cells May Change the Treatment of Elderly Patients With Acute Myeloblastic Leukemia.
    Exp Hematol. 2016 Nov 5. pii: S0301-472X(16)30662.
    PubMed     Text format     Abstract available


    October 2016
  31. DWIVEDI P, Greis KD
    Granulocyte Colony Stimulating Factor Receptor (G-CSFR) signaling in severe congenital neutropenia, chronic neutrophilic leukemia and related malignancies.
    Exp Hematol. 2016 Oct 24. pii: S0301-472X(16)30663.
    PubMed     Text format     Abstract available


  32. ZHOU L, Wang Q, Chen X, Fu L, et al
    AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia.
    Exp Hematol. 2016 Oct 7. pii: S0301-472X(16)30649.
    PubMed     Text format     Abstract available


  33. DEVEAU AP, Bentley VL, Berman JN
    Using zebrafish models of leukemia to streamline drug screening and discovery.
    Exp Hematol. 2016 Oct 6. pii: S0301-472X(16)30648.
    PubMed     Text format     Abstract available


    September 2016
  34. YANAGISAWA B, Ghiaur G, Smith BD, Jones RJ, et al
    Translating Leukemia Stem Cells into the Clinic: Harmonizing the Heterogeneity.
    Exp Hematol. 2016 Sep 28. pii: S0301-472X(16)30572.
    PubMed     Text format     Abstract available


  35. BASHFORD-ROGERS RJ, Palser AL, Hodkinson C, Baxter J, et al
    Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.
    Exp Hematol. 2016 Sep 28. pii: S0301-472X(16)30622.
    PubMed     Text format     Abstract available


  36. PARK M, Park CJ, Cho YW, Jang S, et al
    Alterations in bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia and normal bone marrow.
    Exp Hematol. 2016 Sep 27. pii: S0301-472X(16)30621.
    PubMed     Text format     Abstract available


  37. WEIDEMANN RR, Behrendt R, Schoedel KB, Muller W, et al
    Constitutive Kit activity triggers B cell acute lymphoblastic leukemia-like disease in mice.
    Exp Hematol. 2016 Sep 21. pii: S0301-472X(16)30615.
    PubMed     Text format     Abstract available


  38. SCHNEIDER E, Staffas A, Rohner L, Krowiorz K, et al
    MicroRNA-155 is upregulated in MLL rearranged AML but its absence does not affect leukemia development.
    Exp Hematol. 2016 Sep 9. pii: S0301-472X(16)30597.
    PubMed     Text format     Abstract available


    July 2016
  39. LAVERDIERE I, Boileau M, Herold T, Rak J, et al
    Complement Cascade Gene Expression Defines Novel Prognostic Subgroups of Acute Myeloid Leukemia.
    Exp Hematol. 2016 Jul 26. pii: S0301-472X(16)30514.
    PubMed     Text format    


  40. RUCKER-BRAUN E, Link CS, Schmiedgen M, Tunger A, et al
    Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation.
    Exp Hematol. 2016 Jul 26. pii: S0301-472X(16)30510.
    PubMed     Text format     Abstract available


  41. ZHAO L, Eric So CW
    PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment.
    Exp Hematol. 2016 Jul 26. pii: S0301-472X(16)30509.
    PubMed     Text format     Abstract available


    June 2016
  42. KOJIMA K, Ishizawa J, Andreeff M
    Pharmacological activation of wild-type p53 in the therapy of leukemia.
    Exp Hematol. 2016 Jun 17. pii: S0301-472X(16)30139.
    PubMed     Text format     Abstract available


    May 2016
  43. ECKSTEIN OS, Wang L, Punia JN, Kornblau SM, et al
    Mixed Phenotype Acute Leukemia (MPAL) Exhibits Frequent Mutations in DNMT3A and Activated Signaling Genes.
    Exp Hematol. 2016 May 18. pii: S0301-472X(16)30128.
    PubMed     Text format     Abstract available


  44. GRIFFITH M, Griffith OL, Krysiak K, Skidmore ZL, et al
    Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B lymphoblastic leukemia.
    Exp Hematol. 2016 May 12. pii: S0301-472X(16)30115.
    PubMed     Text format     Abstract available


  45. TESTA U, Labbaye C, Castelli G, Pelosi E, et al
    Oxidative Stress and Hypoxia in Normal and Leukemic Stem Cells.
    Exp Hematol. 2016 May 11. pii: S0301-472X(16)30116.
    PubMed     Text format     Abstract available


  46. KADONO M, Kanai A, Nagamachi A, Shinriki S, et al
    Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia.
    Exp Hematol. 2016 May 9. pii: S0301-472X(16)30125.
    PubMed     Text format     Abstract available


  47. ZHANG J, Liu X, Lin Y, Li Y, et al
    HnRNP K contributes to drug resistance in acute myeloid leukemia through the regulation of autophagy.
    Exp Hematol. 2016 May 4. pii: S0301-472X(16)30118.
    PubMed     Text format     Abstract available


  48. YANG YG, Sari IN, Zia MF, Lee SR, et al
    Tetraspanins: Spanning from solid tumors to hematologic malignancies.
    Exp Hematol. 2016;44:322-8.
    PubMed     Text format     Abstract available


  49. BOSSE RC, Wasserstrom B, Meacham A, Wise E, et al
    Chemosensitizing AML cells by targeting bone marrow endothelial cells.
    Exp Hematol. 2016;44:363-377.
    PubMed     Text format     Abstract available


    April 2016
  50. RIEGER CT, Fiegl M
    Microenvironmental oxygen partial pressure in acute myeloid leukemia: is there really a role for hypoxia?
    Exp Hematol. 2016 Apr 23. pii: S0301-472X(16)30082.
    PubMed     Text format     Abstract available


  51. BYRNE M, Savani BN, Mohty M, Nagler A, et al
    Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Exp Hematol. 2016 Apr 19. pii: S0301-472X(16)30077.
    PubMed     Text format     Abstract available


    March 2016
  52. WANG QY, Zhong H, Chen FY, Zhang MY, et al
    A preliminary study on epigenetic regulation of Acanthopanax senticosus in leukemia cell lines.
    Exp Hematol. 2016 Mar 15. pii: S0301-472X(16)30031.
    PubMed     Text format     Abstract available


  53. HOOFD C, Wang X, Lam S, Jenkins C, et al
    CD44 promotes chemoresistance in T-ALL by increased drug efflux.
    Exp Hematol. 2016;44:166-71.
    PubMed     Text format     Abstract available


  54. ISHIBASHI T, Yaguchi A, Terada K, Ueno-Yokohata H, et al
    Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
    Exp Hematol. 2016;44:177-88.
    PubMed     Text format     Abstract available


    February 2016
  55. KUO YH, Qi J, Cook GJ
    Regain control of p53: targeting leukemia stem cells by isoform-specific HDAC inhibition.
    Exp Hematol. 2016 Feb 25. pii: S0301-472X(16)00071.
    PubMed     Text format     Abstract available


  56. CERABONA D, Sun Z, Nalepa G
    Leukemia and chromosomal instability in aged Fancc-/- mice.
    Exp Hematol. 2016 Feb 6. pii: S0301-472X(16)00038.
    PubMed     Text format     Abstract available


  57. PIZZO RJ, Azadniv M, Guo N, Acklin J, et al
    Phenotypic, Genotypic, and Functional Characterization of Normal and Acute Myeloid Leukemia-Derived Marrow Endothelial Cells.
    Exp Hematol. 2016 Feb 3. pii: S0301-472X(16)00037.
    PubMed     Text format     Abstract available


  58. SCHMOHL J, Santovito D, Guenther T, Sutanto W, et al
    Expression of surface-associated 82kDa-proMMP-9 in primary acute leukemia blast cells inversely correlates with patients' risk.
    Exp Hematol. 2016 Feb 1. pii: S0301-472X(16)00036.
    PubMed     Text format     Abstract available


    January 2016
  59. CHEN WS, Zhu HH, Feng GS
    Treating Leukemia at Risk of Inducing Severe Anemia.
    Exp Hematol. 2016 Jan 27. pii: S0301-472X(16)00033.
    PubMed     Text format     Abstract available


  60. ISHIBASHI T, Yokota T, Tanaka H, Ichii M, et al
    ESAM is a novel human hematopoietic stem cell marker associated with a subset of human leukemias.
    Exp Hematol. 2016 Jan 13. pii: S0301-472X(16)00005.
    PubMed     Text format     Abstract available


    December 2015
  61. SUN WT, Xiang W, Ng BL, Asari K, et al
    Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
    Exp Hematol. 2015 Dec 17. pii: S0301-472X(15)00799.
    PubMed     Text format     Abstract available


  62. DOLNIKOV A, Shen S, Klamer G, Joshi S, et al
    Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
    Exp Hematol. 2015;43:1001-1014.
    PubMed     Text format     Abstract available


    November 2015
  63. TZORAN I, Rebibo-Sabbah A, Brenner B, Aharon A, et al
    Disease dynamics in patients with acute myeloid leukemia: new biomarkers.
    Exp Hematol. 2015;43:936-43.
    PubMed     Text format     Abstract available


  64. NAKAMURA D, Yoshimitsu M, Kuroki A, Hachiman M, et al
    A new ATL xenograft model and evaluation of pyrrolidine dithiocarbamate as a potential ATL therapeutic agent.
    Exp Hematol. 2015;43:944-50.
    PubMed     Text format     Abstract available


  65. DANIS E, Yamauchi T, Echanique K, Haladyna J, et al
    Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
    Exp Hematol. 2015;43:930-935.
    PubMed     Text format     Abstract available


    October 2015
  66. MANUKJAN G, Ripperger T, Santer L, von Neuhoff N, et al
    Expression of the ETS transcription factor GABPalpha is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Exp Hematol. 2015;43:880-90.
    PubMed     Text format     Abstract available


  67. KING KY, Matatall KA, Shen CC, Goodell MA, et al
    Comparative long-term effects of interferon alpha and hydroxyurea on human hematopoietic progenitor cells.
    Exp Hematol. 2015;43:912-918.
    PubMed     Text format     Abstract available


    September 2015
  68. SAUER T, Arteaga MF, Isken F, Rohde C, et al
    MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML.
    Exp Hematol. 2015;43:794-802.
    PubMed     Text format     Abstract available


  69. CHAUDHURY SS, Morison JK, Gibson BE, Keeshan K, et al
    Insights into cell ontogeny, age, and acute myeloid leukemia.
    Exp Hematol. 2015;43:745-55.
    PubMed     Text format     Abstract available


    May 2015
  70. IIZUKA H, Kagoya Y, Kataoka K, Yoshimi A, et al
    Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
    Exp Hematol. 2015 May 25. pii: S0301-472X(15)00170.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: